FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103784384> ?p ?o ?g. }

• W2103784384 endingPage "S567" @default.
• W2103784384 startingPage "S566" @default.
• W2103784384 abstract "Purpose/Objective(s)Cancer survivors may be at significant risk for late effects after radiotherapy therapy. The impact of toxicity after cancer treatment on survivors is not well described. This Internet based study evaluates patient perceptions of toxicity after radiation therapy.Materials/MethodsPatient-reported data was gathered via a convenience sample frame from cancer survivors voluntarily utilizing a publically available, free, Internet-based tool for creation of survivorship care plans. Available at www.livestrongcareplan.com and through the OncoLink website, the tool allows survivors to enter data regarding diagnosis, demographics, and treatments, and provides customized guidelines for future care. During use of the tool, survivors are queried regarding late effects associated with specific treatments, and asked to answer “yes,” “no,” or “I don't know.” They are also asked to score GI and GU toxicity using modified versions of validated scales. All data have been maintained with institutional review board approval.ResultsOf 3223 cancer survivors answering queries regarding late effects, 1785 (55%) had undergone radiotherapy (78% women, 88% Caucasian). Their most common diagnoses were breast (53%), lymphoma/leukemia (10%), GI (8%), and GU (8%) cancers. Median time from diagnosis was 2.3 years. Of the whole cohort, the most common late effects reported were concern regarding cognitive changes (58%), sexual changes (55%), changes in texture/color of skin (50%), and chronic pain/numbness/tingling (39%). Late effects by disease site are outlined in Table 1.ConclusionsTabled 1Most commonly reported late effects by cancer survivors after radiation according to diagnosisDiagnosis# UsersPatient Reported OutcomesBreast Cancer944 (53%)Cognitive changes (62%)Skin changes (53%)Chronic pain/ numbness/ tingling (53%)Loss of flexibility (34%)Leukemia/ lymphoma181 (10%)Cognitive changes (50%)Sexual changes (49%)Skin changes (46%)Hypothyroid (40%)Gastrointestinal160 (9%)Cognitive changes (50%)Sexual changes (44%)Chronic diarrhea (32%)Skin changes (23%)Genitourinary145 (8%)Sexual changes (56%)Urinary incontinence (20%)Skin changes (18%)Osteoporosis (12%)Head and Neck90 (5%)Decreased saliva (83%)Difficulty speaking/swallowing (80%)Skin changes (70%)Loss of neck flexibility (57%)Gynecologic88 (5%)Sexual changes (78%)Cognitive changes (49%)Skin changes (40%)Weight gain (33%)Lung51 (3%)Skin changes (44%)Chronic pain/ numbness/ tingling (43%)Hearing loss (34%)Hypothyroid (29%) Open table in a new tab Purpose/Objective(s)Cancer survivors may be at significant risk for late effects after radiotherapy therapy. The impact of toxicity after cancer treatment on survivors is not well described. This Internet based study evaluates patient perceptions of toxicity after radiation therapy. Cancer survivors may be at significant risk for late effects after radiotherapy therapy. The impact of toxicity after cancer treatment on survivors is not well described. This Internet based study evaluates patient perceptions of toxicity after radiation therapy. Materials/MethodsPatient-reported data was gathered via a convenience sample frame from cancer survivors voluntarily utilizing a publically available, free, Internet-based tool for creation of survivorship care plans. Available at www.livestrongcareplan.com and through the OncoLink website, the tool allows survivors to enter data regarding diagnosis, demographics, and treatments, and provides customized guidelines for future care. During use of the tool, survivors are queried regarding late effects associated with specific treatments, and asked to answer “yes,” “no,” or “I don't know.” They are also asked to score GI and GU toxicity using modified versions of validated scales. All data have been maintained with institutional review board approval. Patient-reported data was gathered via a convenience sample frame from cancer survivors voluntarily utilizing a publically available, free, Internet-based tool for creation of survivorship care plans. Available at www.livestrongcareplan.com and through the OncoLink website, the tool allows survivors to enter data regarding diagnosis, demographics, and treatments, and provides customized guidelines for future care. During use of the tool, survivors are queried regarding late effects associated with specific treatments, and asked to answer “yes,” “no,” or “I don't know.” They are also asked to score GI and GU toxicity using modified versions of validated scales. All data have been maintained with institutional review board approval. ResultsOf 3223 cancer survivors answering queries regarding late effects, 1785 (55%) had undergone radiotherapy (78% women, 88% Caucasian). Their most common diagnoses were breast (53%), lymphoma/leukemia (10%), GI (8%), and GU (8%) cancers. Median time from diagnosis was 2.3 years. Of the whole cohort, the most common late effects reported were concern regarding cognitive changes (58%), sexual changes (55%), changes in texture/color of skin (50%), and chronic pain/numbness/tingling (39%). Late effects by disease site are outlined in Table 1. Of 3223 cancer survivors answering queries regarding late effects, 1785 (55%) had undergone radiotherapy (78% women, 88% Caucasian). Their most common diagnoses were breast (53%), lymphoma/leukemia (10%), GI (8%), and GU (8%) cancers. Median time from diagnosis was 2.3 years. Of the whole cohort, the most common late effects reported were concern regarding cognitive changes (58%), sexual changes (55%), changes in texture/color of skin (50%), and chronic pain/numbness/tingling (39%). Late effects by disease site are outlined in Table 1. ConclusionsTabled 1Most commonly reported late effects by cancer survivors after radiation according to diagnosisDiagnosis# UsersPatient Reported OutcomesBreast Cancer944 (53%)Cognitive changes (62%)Skin changes (53%)Chronic pain/ numbness/ tingling (53%)Loss of flexibility (34%)Leukemia/ lymphoma181 (10%)Cognitive changes (50%)Sexual changes (49%)Skin changes (46%)Hypothyroid (40%)Gastrointestinal160 (9%)Cognitive changes (50%)Sexual changes (44%)Chronic diarrhea (32%)Skin changes (23%)Genitourinary145 (8%)Sexual changes (56%)Urinary incontinence (20%)Skin changes (18%)Osteoporosis (12%)Head and Neck90 (5%)Decreased saliva (83%)Difficulty speaking/swallowing (80%)Skin changes (70%)Loss of neck flexibility (57%)Gynecologic88 (5%)Sexual changes (78%)Cognitive changes (49%)Skin changes (40%)Weight gain (33%)Lung51 (3%)Skin changes (44%)Chronic pain/ numbness/ tingling (43%)Hearing loss (34%)Hypothyroid (29%) Open table in a new tab" @default.
• W2103784384 created "2016-06-24" @default.
• W2103784384 creator A5005086666 @default.
• W2103784384 creator A5036406812 @default.
• W2103784384 creator A5064662102 @default.
• W2103784384 creator A5071888692 @default.
• W2103784384 creator A5091328132 @default.
• W2103784384 date "2011-10-01" @default.
• W2103784384 modified "2023-10-18" @default.
• W2103784384 title "Outcomes Reported by Cancer Survivors after Radiation Therapy" @default.
• W2103784384 doi "https://doi.org/10.1016/j.ijrobp.2011.06.899" @default.
• W2103784384 hasPublicationYear "2011" @default.
• W2103784384 type Work @default.
• W2103784384 sameAs 2103784384 @default.
• W2103784384 citedByCount "0" @default.
• W2103784384 crossrefType "journal-article" @default.
• W2103784384 hasAuthorship W2103784384A5005086666 @default.
• W2103784384 hasAuthorship W2103784384A5036406812 @default.
• W2103784384 hasAuthorship W2103784384A5064662102 @default.
• W2103784384 hasAuthorship W2103784384A5071888692 @default.
• W2103784384 hasAuthorship W2103784384A5091328132 @default.
• W2103784384 hasConcept C121608353 @default.
• W2103784384 hasConcept C126322002 @default.
• W2103784384 hasConcept C172400760 @default.
• W2103784384 hasConcept C509974204 @default.
• W2103784384 hasConcept C512399662 @default.
• W2103784384 hasConcept C530470458 @default.
• W2103784384 hasConcept C71924100 @default.
• W2103784384 hasConcept C72563966 @default.
• W2103784384 hasConceptScore W2103784384C121608353 @default.
• W2103784384 hasConceptScore W2103784384C126322002 @default.
• W2103784384 hasConceptScore W2103784384C172400760 @default.
• W2103784384 hasConceptScore W2103784384C509974204 @default.
• W2103784384 hasConceptScore W2103784384C512399662 @default.
• W2103784384 hasConceptScore W2103784384C530470458 @default.
• W2103784384 hasConceptScore W2103784384C71924100 @default.
• W2103784384 hasConceptScore W2103784384C72563966 @default.
• W2103784384 hasIssue "2" @default.
• W2103784384 hasLocation W21037843841 @default.
• W2103784384 hasOpenAccess W2103784384 @default.
• W2103784384 hasPrimaryLocation W21037843841 @default.
• W2103784384 hasRelatedWork W2004846284 @default.
• W2103784384 hasRelatedWork W2011306740 @default.
• W2103784384 hasRelatedWork W2086127676 @default.
• W2103784384 hasRelatedWork W2133199694 @default.
• W2103784384 hasRelatedWork W2330553579 @default.
• W2103784384 hasRelatedWork W2384708512 @default.
• W2103784384 hasRelatedWork W2603773853 @default.
• W2103784384 hasRelatedWork W2887621906 @default.
• W2103784384 hasRelatedWork W2990081379 @default.
• W2103784384 hasRelatedWork W4322772323 @default.
• W2103784384 hasVolume "81" @default.
• W2103784384 isParatext "false" @default.
• W2103784384 isRetracted "false" @default.
• W2103784384 magId "2103784384" @default.
• W2103784384 workType "article" @default.